Skip to main content

News

August 22, 2024 in Homepage News, News Highlight

Ractigen Therapeutics Announces U.S. FDA Orphan Drug Designation (ODD) granted to RAG-18 for the treatment of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy

JIANGSU, China, August 22, 2024 – Ractigen Therapeutics, a pioneering developer of small activating RNA…
Read More
January 27, 2022 in Company News, Homepage News

Ractigen Therapeutics closes an additional $30 million in Series A+ funding to push development of its RNAa platform

Ractigen Therapeutics today announced the closing of a Series A+ financing round totaling $30 million…
Read More
February 10, 2021 in Company News, Homepage News

Ractigen Therapeutics closes on $17 Million Series A to advance lead program into clinical phase, led by Hillhouse Venture Capital

Ractigen Therapeutics, a leading company in the saRNA drug space, announced that it has closed…
Read More
May 19, 2020 in Company News, Homepage News

CB Insights lists Ractigen as one of the Top RNA biotech companies in China

Today, CB Insights China published, for the first time, a top list of RNA biotech…
Read More
Close Menu